Agostini M, Marconi L, Mónaco MC

Language: Spanish
References: 20
Page: 67-69
PDF size: 265.10 Kb.

ABSTRACT

Antiretroviral therapy in HIV patients has achieved a chronicity of the disease for which these patients reach more advanced ages. Hypertension is a major concern for our patients. Adequate metabolic control, and the establishment of a proper treatment, are aspects which necessarily have to be analyzed.

REFERENCES

1. Galvan V, Puerto MJ, Mas J. Hipertensión arterial en pacientes infectados por el virus de la inmunodeficiencia humana. Hipertensión. 2003;20(2):63-73.

2. Lupo S. El paciente con hiv y Sida. En: Alcides G, Gallo R, Parodi R, Carlson D. Terapéutica Clínica, tomo1. 2ª ed.; Argentina: Corpus editorial; 2011. 655-66.

3. Nguyen KA, Peer N, Mills EJ, Kengne AP. Burden, Determinants, and Pharmacological Management of Hypertension in hiv-Positive Patients and Populations: A Systematic Narrative Review. aids Rev. 2015;17(2):83-95.

4. Antonello VS, Ferreira Antonello C, Grossmann TK, Tovo CV, Brasil Dal Pupo B, De Quadros Winckler L. Hypertension-an emerging cardiovascular risk factor in hiv infection. J Am Soc Hypertens. 2015;9(5):403-7.

5. Havlir DV, Currier JS. croi 2015: Complications of hiv Infection and Antiretroviral Therapy. Top Antivir Med. 2015;23(1):56-65.

6. Myerson M, Poltavskiy E, Armstrong EJ, Kim S, Sharp V, Bang H. Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 hiv outpatients. J Acquir Immune Defic Syndr. 2014;66(4):370-7.

7. Stansell J, Gary D, Slaker R, Hamel E, Lapins D. Trends in comorbidities, utilization and cost care in hiv+ patients 1996-1999. xiii International aids Conference. Durban, Sudáfrica, 9-14 julio 2000.

8. Jericó C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalencia de factores de riesgo cardiovascular en pacientes con infección por el vih. Revista clinica espanola, 2006;206(11):556-9.

9. Petoumenos K, Worm S, Reiss P, De Wit S, D’Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with hiv infection: results from the dad study. hiv medicine. 2011;12(7):412-21.

10. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte ADA, dad Study Group. Cardiovascular disease risk factors in hiv patients–association with antiretroviral therapy. Results from the dad study. Aids. 2003;17(8):1179-93.

11. Sherer R. hiv, haart, and hyperlipidemia: balancing the effects. J. Acquir. Immune Defic. Syndr. [Internet] 2003;34(Suppl. 2):S123-9. Disponible en: doi: 10.1097/00126334- 200310012-00005.

12. Calvo M. Update on metabolic issues in hiv patients. Curr Opin hiv aids. 2014;9(4):332-9.

13. Nakanjako D, Ssinabulya I, Nabatanzi R, et al. Atorvastatin reduces T-cell activation and exhaustion among hiv-infected cart-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health. 2015;20(3):380-90.

14. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. hiv Outpatient Study (hops) Investigators Low cd4+ T cell count is a risk factor for cardiovascular disease events in the hiv outpatient study. Clin. Infect. Dis. [Internet] 2010;51(4):435-47. Disponible en: doi: 10.1086/655144.

15. Aoun S, Ramos S. Hypertension in the hiv-infected patient. Curr Hypertens Rep. 2000;2:478-81.

16. Szczech LA. Hypertension and medicationrelated renal dysfunction in the hiv-infected patient. Semin Nephrol. 2001;21:386-93.

17. Anderson M. Is the incidence of hypertension higher in hiv infected persons on arv therapy? hiv Clin. 2001;13:1-4.

18. Chastain DB, Henderson H, Stover KR. Epidemiology and Management of Antiretroviral- Associated Cardiovascular Disease. The Open aids Journal. [Internet] 2015;9:23-7. Dsiponible en: doi:10.2174/18746136015090 10023.

19. Reut C. Common Adverse Effects of Antiretroviral Therapy for hiv Disease. Am Fam Physician. 2011;83(12):1443-51.

20. Chu C, Selwyn N. Diagnosis and Initial Management of Acute hiv Infection. Am Fam Physician. 2010;81(10):1239-44.